Rani Jarkas: Cross-border innovation and investment in China’s life science industry

As China’s economy continues to surge and move up the product cycle, the country is on track to become a global leader in life sciences innovation and manufacturing. Foreign firms, which hold a 30 percent share of the local market, are rapidly expanding their biotech investments in China – in manufacturing, joint ventures, and R&D — yet they continue to face many challenges.

With the recently announced positive regulatory and compliance policy reforms, China’s life science industry is set to boom. Released in March 2016, China’s thirteenth Five-Year Plan reinforces the country’s focus on “innovative development” with additional emphasis on “biological technology.”

Besides domestic innovation, entrepreneurs in the field have also created cross-border business models, including investments in global clinical stage candidates and international collaborations for the best efficiency.

China continues to be a hotbed for partnering activity, more than doubling in 2015 to over US$4 billion in total announced deal value. Traditionally, Chinese partners tend to contribute heavily on infrastructure and other local resources performing a more “CRO-oriented” role. However, there has also been a rise in Chinese biotechs with truly innovative drug candidates that have attracted the attention of foreign pharms.

Cross-border partnership is developing a network across academics, business and clinicians to drive innovation in China’s healthcare industry. The ultimate objective is to improve treatments, diagnoses and quality of life for patients in China but will also lead to a huge number of business opportunities and will develop China’s capabilities as an innovation destination.

Rani Jarkas, Chairman of Cedrus Investments, an investment pioneer with years of experience in biotech and life science sector, said, “China’s pursuit of a domestic life science sector will benefit the Chinese people, local entrepreneurs, and multinationals who are hungry to identify solutions designed to reflect China’s unique healthcare challenges.”

Rani Jarkas, the Chairman of Cedrus Investments.

Rani Jarkas is a highly experienced financial services executive, with over 20 years of international banking experience. Currently, Mr. Jarkas is the Chairman of Cedrus Investments, a global boutique investment firm. Cedrus’ domain expertise is in life sciences, natural resources, energy, cleantech and nanotechnology. – Rani Jarkas

 

Advertisements

王雷(Rani Jarkas):中国生物科技产业的跨境创新和投资

随着中国经济持续飞速发展,并在产品周期循环内向上移动,整个国家正在成为生命科学创新生产领域的全球领导者。外国公司在本土市场占到约30%,也正在加速在中国的生物科技投资——在生产、合资企业和科研方面——但目前也仍然面临许多挑战。

中国近期公布了有利的监管和合规政策改革,推动了生命科学产业的蓬勃发展。2016年3月发布的中国“十三五”计划,再次强调了国家的重心是在“创新发展”,格外关注“生物科技”。

除了国内的创新,该领域的企业家们也开创了众多跨境交易模式,包括投资全球临床阶段产品和全球合作,以期获得最佳的效果。

中国继续成为合作活动的热点地区,2015年的交易额翻了一番,达到了40亿美元。传统意义上,中国合作者通常主要贡献在基础设施和其他当地资源,更多地担任了“临床研究机构”的角色。然而,中国的生物科技领域出现了一批真正的创新药物产品,吸引了国际药企的关注。

跨境合作正在学术研究机构、商业和临床医生间建立起网络,推动中国医疗产业的创新。最终的目标是提高中国的治疗、诊断和病人生活质量,但同时也会创造出数量庞大的商业机会,发展中国成为创新集聚地的能力。

赛德思投资董事长王雷(Rani Jarkas)在生物科技领域有多年的投资经验。他表示:“中国对国内生命科学产业的追求将造福于中国人民、本土企业以及那些公司渴望寻找到中国医疗独特挑战解决方案的跨国公司。”

Rani Jarkas, the Chairman of Cedrus Investments.

Rani Jarkas is a highly experienced financial services executive, with over 20 years of international banking experience. Currently, Mr. Jarkas is the Chairman of Cedrus Investments, a global boutique investment firm. Cedrus’ domain expertise is in life sciences, natural resources, energy, cleantech and nanotechnology. – Rani Jarkas